BRIEF-Genmab expects royalties of 31 mln DKK in Q3

COPENHAGEN Wed Oct 23, 2013 7:14am EDT

Related Topics

COPENHAGEN Oct 23 (Reuters) - Danish biotech firm Genmab said on Wednesday:

* Net sales of blood cancer drug Arzerra (ofatumumab) during the third quarter of 2013 were 17.8 million GBP

* Expects to receive a royalty payment of approximately 31 million Danish crowns ($5.72 million) from its partner British GlaxoSmithKline Further company coverage:

FILED UNDER: